Accessibility Menu
Arrow-Thin-Down
S&P 500
6,901.64
+0.2%
+10.75
Arrow-Thin-Down
DJI
47,832.11
+0.3%
+125.74
Arrow-Thin-Down
NASDAQ
23,954.09
+0.5%
+126.60
Arrow-Thin-Down
Bitcoin
$111,896.00
-3.0%
-$3,494.63
Arrow-Thin-Down
AAPL
$270.56
+0.6%
+$1.56
Arrow-Thin-Down
AMZN
$229.89
+0.3%
+$0.64
Arrow-Thin-Down
GOOG
$273.36
+1.8%
+$4.93
Arrow-Thin-Down
META
$747.85
-0.5%
-$3.59
Arrow-Thin-Down
MSFT
$538.89
-0.6%
-$3.18
Arrow-Thin-Down
NVDA
$206.92
+2.9%
+$5.89
Arrow-Thin-Down
TSLA
$461.39
+0.2%
+$0.84
Daily Stock GainersDaily Stock LosersMost Active Stocks
Finch Therapeutics Group Stock Quote

Finch Therapeutics Group (OTC: FNCH)

$13.64
(1.0%)
+0.14
Price as of October 29, 2025, 11:15 a.m. ET

KEY DATA POINTS

Current Price
$13.64
Daily Change
(1.0%) +$0.14
Day's Range
$13.55 - $13.70
Previous Close
$13.50
Open
$13.55
Beta
0.56
Volume
5,883
Average Volume
2,327
Sector
Health Care
Market Cap
21.7M
Market Cap / Employee
$13.50M
52wk Range
$10.15 - $15.85
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
$0.00
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Finch Therapeutics Group Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
FNCH+14.89%N/AN/A-98%
S&P+18.33%+108.18%+15.79%+76%

Finch Therapeutics Group Company Info

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Somerville, MA.

News & Analysis

Featured Article

Why Finch Therapeutics Stock Is Skyrocketing Today

The FDA, at long last, has lifted a clinical hold on Finch's C. diff program.

Keith Speights  |  Apr 29, 2022

Financial Health

General

Q2 2024YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.04M0.0%
Market Cap$2.20M0.0%
Market Cap / Employee$2.20M0.0%
Employees10.0%
Net Income-$4.83M0.0%
EBITDA-$6.07M0.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2024YOY Change
Net Cash$16.04M0.0%
Accounts Receivable$0.00M0.0%
Inventory00.0%

Liabilities

Q2 2024YOY Change
Long Term Debt$26.90M0.0%
Short Term Debt$2.09M0.0%

Ratios

Q2 2024YOY Change
Return On Assets-25.20%0.0%
Return On Invested Capital-61.24%0.0%

Cash Flow

Q2 2024YOY Change
Free Cash Flow-$4.73M0.0%
Operating Free Cash Flow-$4.73M0.0%

Valuation

MetricQ4 2023Q1 2024Q2 2024YoY Change
Price to Book0.220.180.12-
Price to Sales54.18-
Price to Tangible Book Value0.220.180.12-
Enterprise Value to EBITDA-2.33-2.53-2.50-
Return on Equity-128.7%-62.6%-67.3%-
Total Debt$30.13M$29.56M$28.99M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services